Blood Research

Assessment of hemostatic effectiveness (efficacy analysis set, N=54).

Treatment type N of assessments (%) N of patients (%)b)
Treatment of bleedinga)
Total 66 25c)
None 0 (0.0) 0 (0.0)
Fair 11 (16.7) 7 (28.0)
Good 50 (75.8) 17 (68.0)
Excellent 5 (7.6) 4 (16.0)
Effective (excellent+good) 55 (83.3) 18 (72.0)
Prophylaxisa)
Total 76 40c)
None 0 (0.0) 0 (0.0)
Fair 8 (10.5) 5 (12.5)
Good 47 (61.8) 32 (80.0)
Excellent 21 (27.6) 17 (42.5)
Effective (excellent+good) 68 (89.5) 35 (87.5)
Overall treatment typea)
Total 142 54c)
None 0 (0.0) 0 (0.0)
Fair 19 (13.4) 12 (22.2)
Good 97 (68.3) 43 (79.6)
Excellent 26 (18.3) 20 (37.0)
Effective (excellent+good) 123 (86.6) 42 (77.8)

a)In case an assessment is performed by the patient as well as by the physician, then the worst-case assessment is considered. b)For the ratings “None,” “Fair,” “Good,” or “Excellent,” each patient could rate more often. For the rating “Good” or “Excellent,” in case a patient had more than one assessment, the worst-case assessment is considered for this patient. c)Number of unique patients with an effectiveness assessment available in the respective “Treatment type/Assessor.”

Blood Res 2020;55:246~252 https://doi.org/10.5045/br.2020.2020225
© Blood Research
© 2024. BLOOD RESEARCH All rights reserved. Powered by INFOrang Co., Ltd